Platelet Agregation in Patients on ECMO

Status Recruiting

Clinical Trial Summary

An observational study in which investigators will observe platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor.

Clinical Trial Description

Investigators will perform an observational study in which platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor will be observed. Participants will be divided into three groups: A: patients on V-A ECMO without P2Y12 inhibitors B patients on V-A ECMO with P2Y12 inhibitors with administration of P2Y12 inhibitor at the time of ECMO insertion C: patients on V-A ECMO already recieving P2Y12 inhibitors at the time of ECMO insertion. Blood samples will be taken prior to and at 2, 4, 12, 22, 48, 72 after ECMO insertion and after removal of an ECMO. VerifyNow System will be used to measure platelet agregation (PRU test). ;

Study Design

Related Conditions & MeSH terms

Platelet Refractoriness

Clinical Trial Details

NCT number	NCT05542134
Study type	Observational
Source	University Medical Centre Ljubljana
Contact	Marko Noc, MD, phD
Phone	+38641723807
Email	marko.noc@kclj.si
Status	Recruiting
Phase
Start date	January 17, 2019
Completion date	June 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05284032` - A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)	Early Phase 1
Terminated	`NCT04631211` - Thrombosomes® in Bleeding Thrombocytopenic Patients Study	Phase 2
Recruiting	`NCT03679858` - Platelet Antisedimentation Rate and Multiplate Exams in Patients on Antiplatelet Therapy and Controls
Completed	`NCT03408158` - HPA Antibodies and the Distribution of Antigen and Antibodies	N/A
Recruiting	`NCT05091684` - Administration of Fibrinogen Concentrate for Refractory Bleeding	Phase 2